Roche Holding said the U.S. Food and Drug Administration approved a test to identify patients with a specific type of breast cancer. The Swiss pharmaceutical company said the FDA backed a label ...

Early warning signs of diabetes, high blood pressure, and other chronic diseases could be lurking in the back of your eye before symptoms start to show. However, a new test at Boots Opticians ...

Patients with HER2-ultralow status have even lower levels of expression than HER2-low, Roche noted in a statement. The Pathway HER2 test was approved as a companion diagnostic for assessing HER2-low ...

1 The Roche Diagnostics Tina-quant® Lipoprotein (a) Gen.2 Molarity assay is an in-vitro test measuring lipoprotein (a) in a person's bloodstream (serum and plasma), and will be broadly available ...

2025 /PRNewswire/ -- Roche announced today that the Tina-quant® Lipoprotein (a) Gen.2 Molarity assay has received 510(k) clearance from the United States Food and Drug Administration (FDA). This will ...

Diabetic Retinopathy Market 2025 Diabetic Retinopathy Market is expected to reach USD 14.31 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.3% from 2024 to 2031. BURLINGAME, CA, UNITE ...

Diabetic Retinopathy Market is expected to reach USD 14.31 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.3% from 2024 to 2031. BURLINGAME, CA, UNITED STATES, January 24, 2025 ...

If someone has concerns about these conditions, they may consider seeking a test for insulin levels and insulin resistance. Learn more about PCOS and diabetes. Preventing these risk factors is not ...

Diabetic Retinopathy Market is expected to reach USD 14.31 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.3% from 2024 to 2031. BURLINGAME, CA ...

Living with diabetes includes monitoring your blood sugar (also called ... The type of drug you take may influence how frequently your healthcare provider recommends you test your blood sugar levels.